Arcturus Therapeutics Holdings Inc.

NasdaqGM:ARCT Lagerbericht

Marktkapitalisierung: US$438.0m

Arcturus Therapeutics Holdings Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Arcturus Therapeutics Holdings hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-1.5%

Rückkaufsrendite

Gesamte Aktionärsrendite-1.5%
Zukünftige Dividendenrendite0%
Wachstum der Dividenden/a
Nächster Dividendenzahlungsterminn/a
Ex-Dividendendatumn/a
Dividende pro Aktien/a
Ausschüttungsquoten/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Nov 14

Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified

Oct 04
Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified

Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation

Sep 06
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 09

Arcturus: A Hidden Gem In The Biotech Sector

Jun 08

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

May 29
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis

Apr 23

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Apr 09
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Feb 06
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking

Arcturus: H1 2024 Rare Disease Drug Data On Deck

Jan 31

Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Jan 11
Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?

Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Dec 14
Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?

Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Sep 14
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business

Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Aug 08
Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates

Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Jul 19
Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

May 18
Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

May 02
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet

Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Dec 28
Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money

Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 23
Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine

Aug 31

Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Aug 15
Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks

Aug 10

Arcturus: Potential Based On Rare Disease Therapy ARCT-810

Jun 07

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ARCT in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ARCT gestiegen sind.


Dividendenrendite im Vergleich zum Markt

Arcturus Therapeutics Holdings Dividendenrendite im Vergleich zum Markt
Wie sieht die Dividendenrendite von ARCT im Vergleich zum Markt aus?
SegmentDividendenrendite
Unternehmen (ARCT)n/a
Untere 25 % des Marktes (US)1.4%
Markt Top 25 % (US)4.3%
Branchendurchschnitt (Biotechs)2.3%
Analystenprognose (ARCT) (bis zu 3 Jahre)0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ARCT im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von ARCT im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.


Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ARCT, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.


Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ARCT keine Ausschüttungen gemeldet hat.


Entdecken Sie dividendenstarke Unternehmen